The specific effect of rasagiline (Azila) on improving Parkinson’s motor symptoms

Rasagiline (Rasagiline) is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor. It is mainly used for early monotherapy or in combination with levodopa in patients with Parkinson's disease (PD) to improve motor symptoms. By inhibiting the activity of MAO-B, rasagiline can reduce the metabolism of dopamine in the brain and increase the concentration of dopamine in the synaptic cleft, thereby improving motor function and alleviating the "on-off" phenomenon.

In clinical studies, rasagiline monotherapy can significantly improve motor scores in patients with early-stage Parkinson's disease. According to the evaluation of the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS) III, after taking rasagiline, the patient's motor function score improved by an average of about 2-4 points, which means that patients have varying degrees of relief in hand tremors, slow movements, and limb stiffness. Research also shows that the drug has long-term stability in maintaining the motor function of early-stage PD patients, and long-term use can delay the worsening of symptoms.

For patients with advanced or intermediate Parkinson's disease treated with levodopa, rasagiline can also improve motor symptoms and prolong "on" time. Clinical data shows that after the combined use of rasagiline and levodopa, patients' daily "on" state time increases by about 1 hour on average, while reducing the duration of "off" state, significantly improving patients' daily living abilities and quality of life. This is particularly important for patients who are long-term dependent on levodopa, as it can help reduce fluctuations and motor complications associated with the medication.

In addition, rasagiline has a good safety profile while improving motor symptoms. Common adverse reactions include headache, joint pain, insomnia or mild gastrointestinal discomfort, most of which are mild to moderate and controllable and do not affect treatment compliance. In general, rasagiline can effectively improve the motor symptoms of patients with Parkinson's disease by increasing the concentration of dopamine in the brain. Whether it is used as a monotherapy in the early stage or in combination with levodopa in the late stage, it can significantly improve motor function and quality of life.

Reference link:https://www.drugs.com